Diligence memo · auto-generated · as of July 2, 2026
Forcyte Biotechnologies, Inc.
Forcyte Biotechnologies, Inc. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Forcyte Biotechnologies, Inc. operates in Pharma, based in LOS ANGELES, CA, USA. Discover drugs that control how much cells "squeeze" to treat disease
Sub-sector tags: pharma.
Capital & rounds (filed)filed
Forcyte Biotechnologies, Inc. has raised $160K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $1.0M on 2018-12-18.
Most recent recorded round closed around 2018-12-18.
Valuation (modeled)modeled
Provath models Forcyte Biotechnologies, Inc. at approximately $7.6M (range $90K–$86M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.54× the median modeled value of Pre-Seed Pharma companies in 2016–2018 (20 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 7.5 yr ago; this sector typically re-raises about every 16 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 20% of Pharma peers (310 compared).
Modeled value ranks above 31% of those peers.
Closest niche peers: vivo-TIL Therapeutics, Inc, JSK Therapeutics, Inc., Kyto Biopharma Inc, Manzara Therapeutics, Inc., Mirata BioPharma, LLC.
Peoplefiled
1 named person on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.